Table 2.
Study characteristics
| Author/Setting (Country/Hospital) | Type of Study | Sample Size (Per Group) and Participant Mean Age ± SD | Diagnostic Criteria or nosology(± additional inclusion criteria) |
|---|---|---|---|
| Bathen et al42 Oslo, Norway |
Single-arm, pilot study | N=12 Age: median=35, range=20-51 y |
Brighton 199810 or Villefranche 19986 |
| Toprak et al24 Izmir, Turkey |
RCT | IG: n=23 Age: 20.3±2.2 y CG: n=23 Age: 21.0±2.2 y |
Brighton 199810 |
| Daman et al22 Shiraz, Iran |
RCT | IG: n=12 Age: 22.25±1.28 y CG: n=12 Age: 21.66±2.0 y |
Brighton 199810 |
| Ferrell et al21 Glasgow, Scotland |
Single-arm, intervention trial | N=20 Age: 27.3±10.4 y |
Brighton 199810 and knee joint pain |
| Hakimi et al43 Lille, France |
Single-arm, retrospective study | N=21 Age: 45±13 y |
Conducted by EDS specialist, with specific nosology/criteria not provided |
| Liaghat et al40 Odense, Denmark |
Single-arm, feasibility study | N=11 Age: 39.3±13.9 y |
2017 EDS classification11 |
| Palmer et al38 London, England |
Pilot RCT | IG: n=15 Age: 37.2±14.1 y CG: n=14 Age: 33.3±9.7 y |
Brighton 199810 |
| Reychler et al41 Brussels, Belgium |
RCT | IG: n=10 Age: 45.8±5.5 y CG: n=10 Age: 53.1±3.4 y |
Brighton 1998,10 2017 EDS classification,11 and reduced inspiratory muscle strength |
| Sahin et al23 Istanbul, Turkey |
RCT | IG: n=15 Age: 25.60±6.0 y CG: n=25 Age: 27.68±7.8 y |
Brighton 199810 |
| To and Alexander39 London, England |
Cohort study | IG: n=47 Age: 34.6±10.6 y CG.a: n=26 Age: 31.8±10.5 y CG.b: n=29 Age: 38.2±9.3 y |
Brighton 199810 and interior knee pain |
Abbreviations: CG, control group; CG.a, control group with generalized joint hypermobility (ie, joint flexibility without multiple site symptoms experience in those with HSD); CG.b, control group without generalized joint hypermobility; IG, intervention group.